Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Myelodysplastic Syndromes 1Multiple Myeloma 1Leukemia, Myeloid, Acute 1Graft vs Host Disease 1

Interventions

Dexamethasone 64Lenalidomide 37daratumumab 34pomalidomide 31Bortezomib 31Specimen Handling 25carfilzomib 23Biopsy 23Cyclophosphamide 21Magnetic Resonance Spectroscopy 18Calcium Dobesilate 18isatuximab 14fludarabine 12dexamethasone acetate 11dexamethasone 21-phosphate 11auricularum 11talquetamab 10iberdomide 10belantamab mafodotin 10selinexor 8Melphalan 8tocilizumab 7X-Rays 7fludarabine phosphate 6elotuzumab 6Nuclear Medicine Department, Hospital 5trametinib 4pembrolizumab 4nirogacestat 4Sirolimus 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Multiple Myeloma × Emapalumab × 30 days × Clear all
NCT07567014 2026-05-06

Emapalumab Prophylaxis of Bispecific T-Cell Engagers (BiTEs) Associated CRS and ICANS

NYU Langone Health

Phase 2 Not yet recruiting
60 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡